Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence TDQVLSVLKGEE
Primary information
sequence IDSeq_8103
Peptide sequenceTDQVLSVLKGEE
CancerPDF_ID CancerPDF_ID394, CancerPDF_ID9285, CancerPDF_ID9574,
PMID19795908,24694173,21533267
Protein NameApolipoprotein C-II,Apolipoprotein C-II,Apolipoprotein C-II
UniprotKB Entry NameAPOC2_HUMAN,APOC2_HUMAN,APOC2_HUMAN
FluidPlasma,Ascites fluid,Serum
M/Z659.35,NA,659.35
Charge2,1,2
Mass (in Da)NA,NA,NA
fdrNA,NA,NA
Profiling TechniqueLC-MS,LTQ-Orbitrap XL,LC-MS
Peptide Identification techniqueMALDI-TOF/TOF,X tandem for peptide identification,LC/MS/MS
Quantification TechniqueLC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring
Labelled/Label FreeLabelled,Label Free,Label Free
FDRless than 7%,NA,1.49
CancerPDF_ID CancerPDF_ID394, CancerPDF_ID9285, CancerPDF_ID9574,
p-ValueNA,NA,NA
SoftwareFlexAnalysis 3.0 and Biotools 3.0 software,"X tandem for peptide identification,Scaffold 2 software for any modification analysis",MASCOT
Length12,12,12
Cancer TypeDuctal adenocarcinoma of the pancreas (DAP),Ovarian cancer,Lung adenocarcinoma
DatabaseNCBI refseq Protein Database,IPI00021856,Swissprot Database (57.4)
ModificationNA,NA,NA
Number of Patients"41 normal, 24 patients",3 ovarian cancer patient and 3 non cancerous control,62 lung adenocarcinoma and 30 healthy control
RegulationNA,Uniquely expressed in ovarian cancer patient,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationNA,NA,MRM-based validation of 19 candidates
SensitivityNA,NA,NA
SpecificityNA,NA,NA
AccuracyNA,NA,NA
Peptide AtlasPeptideAtlas
IEDB